Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples